Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

PPFAS Asset Management appoints Devendra Ghalsashi as Chief Operating Officer

November 18, 2026

Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10

November 18, 2026

From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE

November 18, 2026
Facebook X (Twitter) Instagram
Trending
  • PPFAS Asset Management appoints Devendra Ghalsashi as Chief Operating Officer
  • Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10
  • From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE
  • Samiran Tea Unveils New Product Portfolio, Including 10 Herbal Tea Blends, at Noida Office Inauguration
  • Manav’s ‘Bardic Voices: Where the Horizon Meets, the Magic Begins’ Explores Memory, Humanity, and the Search for Meaning
  • Glen Industries Limited Reports H1 FY27 Results
  • Spreading Bliss Foundation Supports Children in Orphanage
  • Not Just Another Wellness Brand: How Seltyca Is Combining Doctors, Science and Technology
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Health»NovaLead’s Patented Repurposed Drug receives approval from CDSCO for the treatment of Diabetic Foot Ulcer (DFU) for India market
Health

NovaLead’s Patented Repurposed Drug receives approval from CDSCO for the treatment of Diabetic Foot Ulcer (DFU) for India market

By July 25, 2024No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

New Delhi (India), July 25: NovaLead Pharma Private Limited (NovaLead), the pioneer of drug repurposing in India announced today that the drug regulator in India, CDSCO has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need. 

With over 15% -25% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of NovaLead’s patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally, with about 100,000 annual incidences in India alone.

“The approval of this drug marks an important moment for people suffering from DFU, who until now had limited drug options for complete wound closure. Approval of this drug is also a demonstration of effective Public-Private partnership as its development was part funded by BIRAC, a govt. of India initiative.” said Supreet Deshpande, Chief Executive Officer at NovaLead Pharma Pvt. Ltd., Pune – India.

“Although it is a repurposed drug, we developed it as a new drug with comprehensive preclinical and clinical investigations, keeping patient safety at the forefront. Its approval is based on statistically significant positive results over standard of care treatment in a randomised, double blind Phase 3 clinical trial.” said Dr. Sudhir Kulkarni, Vice President- Discovery, at NovaLead. 

This drug is a novel topical gel formulation of Esmolol hydrochloride, which is already approved in several countries for cardiac conditions via intravenous injection. Thus, this novel topical gel discovered and developed by NovaLead is a new indication as well as new formulation to be first launched in India. NovaLead has been granted patents for this drug in several countries including regulated markets of USA, EU and Japan.

Atul Aslekar, COO of NovaLead, mentioned that “a start-up traversing the highly challenging drug development cycle right from discovery to approval, spanning over a decade and half, makes NovaLead a unique success story in Indian pharma”. 

“The drug will be made available to the patients of DFU in India by one of the leading Indian pharmaceutical companies through an exclusive IP licensing arrangement with NovaLead. Going forward, NovaLead will focus on the development of this repurposed drug for regulated markets of USA and Europe.” said Supreet Deshpande.

About Diabetic Foot Ulcer (DFU)

Over 537 million adults are living with diabetes globally and the number is predicted to rise to 643 million by 2030. About 15-25% of diabetics suffer from DFU, at least once in lifetime, with 25% of DFUs eventually requiring amputation. DFU is a leading cause of lower extremity amputation. The five-year mortality post amputation is 46%. DFU is a serious disease with very limited drug options and very high cost of treatment.

About the Drug (Topical gel of Esmolol Hydrochloride)

It will be a prescription medicine used to treat people with diabetic foot ulcer without active clinical infection. Infected DFUs need to be first treated for infection if existing and then put on the drug treatment for wound closure. A doctor will perform independent assessment of DFU to determine the dose to be applied topically on the patient’s DFU.  

About NovaLead Pharma Private Limited (NovaLead)

NovaLead is a pioneer of drug repurposing in India and one of the few companies globally to have completed the whole cycle from discovery to regulatory approval successfully for a repurposed drug. Headquartered in Pune, India NovaLead’s research focus is to find novel repurposed drug treatment for unmet medical needs. 

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Health
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

Related Posts

Continued vigilance is essential to protect India’s polio-free status

November 17, 2026

Apollo Health strengthens its expansion in North India with New Clinic and National Reference Laboratory in Gurugram

November 16, 2026

Aayush Wellness Launches Himalayan Shilajit Drops as Global Shilajit Market is Projected to Reach USD 436.72 Million by 2034, Growing at 8.67% CAGR

November 16, 2026

Comments are closed.

Top Posts

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020

Final Battle – Avengers: Infinity War – Youtube

February 22, 2020
Don't Miss
Business

PPFAS Asset Management appoints Devendra Ghalsashi as Chief Operating Officer

By Arjun SinghNovember 18, 2026

Mr. Devendra Ghalsashi brings over 24 years of experience across mutual funds, AIFs and PMS…

Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10

November 18, 2026

From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE

November 18, 2026

Samiran Tea Unveils New Product Portfolio, Including 10 Herbal Tea Blends, at Noida Office Inauguration

November 18, 2026
Most Popular

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

PPFAS Asset Management appoints Devendra Ghalsashi as Chief Operating Officer

November 18, 2026

Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10

November 18, 2026

From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE

November 18, 2026

Type above and press Enter to search. Press Esc to cancel.